PE02072007A1 - Combined treatment of tumors expressing her - Google Patents

Combined treatment of tumors expressing her

Info

Publication number
PE02072007A1
PE02072007A1 PE0008652006A PE0008652006A PE02072007A1 PE 02072007 A1 PE02072007 A1 PE 02072007A1 PE 0008652006 A PE0008652006 A PE 0008652006A PE 0008652006 A PE0008652006 A PE 0008652006A PE 02072007 A1 PE02072007 A1 PE 02072007A1
Authority
PE
Peru
Prior art keywords
her2
treatment
egfr
quinazolinamida
tumors expressing
Prior art date
Application number
PE0008652006A
Other languages
Spanish (es)
Inventor
Mark X Sliwkowski
Stephen Michael Kelsey
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US70185205P priority Critical
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE02072007A1 publication Critical patent/PE02072007A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

SE REFIERE A UN PROCEDIMIENTO PARA EL TRATAMIENTO DE NEOPLASIAS QUE EXPRESAN EL EGFR Y EL HER2 QUE COMPRENDE LA ADMINISTRACION DE UNA CANTIDAD EFICAZ DE i) UN INHIBIDOR DE LA DIMERIZACION DEL HER2 TAL COMO UN ANTICUERPO CONTRA HER2 EL CUAL ES UN ANTICUERPO HUMANIZADO 2C4 TAL COMO PERTUZUMAB Y ii) UN INHIBIDOR EGFR EL CUAL ES UN COMPUESTO DE 4-QUINAZOLINAMIDA (US 5,747,498) SIENDO PREFERIDO N-(3-ETINILFENIL)-6,7-BIS(METOXIETOXI)-4-QUINAZOLINAMIDA O ERLOTINIB EL CUAL ESTA PRESENTE EN UNA FORMA POLIMORFA CRISTALINA QUE MUESTRA UN PATRON DE DIFRACCION DE RAYOS X DE POLVO CON PICOS DE 6,26; REFERS TO A PROCEDURE FOR THE TREATMENT OF TUMORS EXPRESSING EGFR and HER2 comprising administering an effective amount of i) an inhibitor of dimerization of HER2 AS an antibody against HER2 WHICH IS A humanized antibody 2C4 AS pertuzumab and ii) an EGFR INHIBITOR WHICH IS A 4-QUINAZOLINAMIDA COMPOUND (US 5,747,498) being preferred N- (3-ethynylphenyl) -6,7-bis (methoxyethoxy) -4-QUINAZOLINAMIDA or erlotinib WHICH is present in an CRYSTALLINE FORM polymorph showing a pattern of XRD POWDER WITH PEAKS 6.26; 12,48; 12.48; 13,39; 13.39; 16,96; 16.96; 20,20; 20,20; ENTRE OTROS (2*) O UN ANTICUERPO CONTRA EGFR TAL COMO CETUXIMAB. AMONG OTHERS (2 *) or an antibody against EGFR such as cetuximab. MOSTRANDO ASI UNA ACTIVIDAD ANTINOPLASICA SINERGICA, ADMINISTRANDOSE DE FORMA SIMULTANEA O CONSECUTIVA Y QUE ADEMAS COMPRENDE TRATAR AL PACIENTE A UN TRATAMIENTO ESTANDAR. Thus showing ACTIVITY ANTINOPLASICA synergic administered simultaneously or consecutively and further comprising treating the patient to a standard treatment. SIENDO UTIL EN EL TRATAMIENTO DEL CANCER DE PULMON ESPECIFICAMENTE CANCER DE PULMON DE CELULAS PEQUENAS (SCLC) O NO PEQUENAS (NSCLC), CANCER DE PROSTATA O COLON BEING IN THE TREATMENT OF UTIL LUNG CANCER LUNG CANCER SPECIFICALLY small cell (SCLC) or non-small (NSCLC), prostate or colon cancer
PE0008652006A 2005-07-22 2006-07-18 Combined treatment of tumors expressing her PE02072007A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US70185205P true 2005-07-22 2005-07-22

Publications (1)

Publication Number Publication Date
PE02072007A1 true PE02072007A1 (en) 2007-03-09

Family

ID=37564413

Family Applications (1)

Application Number Title Priority Date Filing Date
PE0008652006A PE02072007A1 (en) 2005-07-22 2006-07-18 Combined treatment of tumors expressing her

Country Status (4)

Country Link
US (3) US8163287B2 (en)
AR (1) AR054566A1 (en)
PE (1) PE02072007A1 (en)
WO (1) WO2007013950A2 (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
RU2294761C2 (en) * 1999-05-14 2007-03-10 Имклон Систимс Инкопэритид Method for treating resistant human tumors with epidermis growth factor receptors antagonists
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CA2407556C (en) * 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
WO2002011677A2 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
EP1615646B1 (en) 2003-04-08 2014-12-24 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
WO2005070020A2 (en) * 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
MXPA06010715A (en) * 2004-03-19 2007-05-23 Imclone Systems Inc Human anti-epidermal growth factor receptor antibody.
AU2005249492B2 (en) * 2004-05-27 2011-09-22 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
GT200500155A (en) * 2004-06-16 2006-05-15 Therapy resistant cancer platinum
MX2007000723A (en) 2004-07-22 2007-03-12 Genentch Inc Her2 antibody composition.
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
JP2008523073A (en) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッドGenentech,Inc. Selection of patients for treatment with Her inhibitors
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
CN104248763A (en) * 2005-03-07 2014-12-31 芝加哥大学 Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
KR20150008926A (en) * 2005-03-11 2015-01-23 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc Synthesis of (R) -N-methylnaltrexone, PHARMACEUTICAL COMPOSITIONS AND USES
AR057325A1 (en) * 2005-05-25 2007-11-28 Progenics Pharm Inc Synthesis (s) -n-methylnaltrexone, pharmaceutical compositions and uses
PE02072007A1 (en) 2005-07-22 2007-03-09 Genentech Inc Combined treatment of tumors expressing her
EP1968633B2 (en) * 2006-01-04 2017-11-01 Institut National de la Santé et de la Recherche Medicale Combination therapy using anti-egfr and anti-her2 antibodies
US20080033039A1 (en) * 2006-06-02 2008-02-07 Wanebo Harold J Combination of ceramide and oxaliplatin for inducing cell death and uses thereof in treating cancer
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
EP2126127B1 (en) * 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
BRPI0808418A2 (en) 2007-03-02 2014-07-22 Genentech Inc Prediction of response to a HER inhibitor
DK2565195T3 (en) 2007-03-29 2015-06-29 Wyeth Llc And peripheral opioid receptor antagonists, and uses thereof
EP3263571A1 (en) 2007-03-29 2018-01-03 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
WO2009015203A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
WO2009015237A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
JP5276103B2 (en) * 2007-08-14 2013-08-28 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Egfr inhibitor therapy marker
AU2008286335B2 (en) * 2007-08-14 2011-10-27 F. Hoffmann-La Roche Ag Predictive marker for EGFR inhibitor treatment
CN101909622B (en) 2007-10-29 2013-06-19 武田药品工业株式会社 Pyrrolo [1,2-C] imidazole derivates for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
WO2009058895A1 (en) * 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
WO2009079547A1 (en) * 2007-12-18 2009-06-25 Smithkline Beecham (Cork) Limited Quinazoline anhydrate forms
US8637026B2 (en) * 2007-12-26 2014-01-28 Vaccinex, Inc. Anti-C35 antibody combination therapies and methods
NZ586946A (en) * 2008-01-18 2012-06-29 Natco Pharma Ltd 6,7-Dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
JP5358587B2 (en) 2008-02-06 2013-12-04 プロジェニックス・ファーマシューティカルス・インコーポレイテッドProgenics Pharmaceuticals, Inc. (R), (r) -2,2'- bis - methylnaltrexone production and use
HUE035184T2 (en) 2008-03-18 2018-05-02 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
US8685995B2 (en) * 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US20110135651A1 (en) * 2008-08-19 2011-06-09 Children's Hospital Medical Center Method and composition for enhancing hematopoietic stem cell mobilization
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN102753193A (en) 2008-10-31 2012-10-24 比奥根艾迪克Ma公司 Light targeting molecules and uses thereof
CN104447995A (en) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 Bispecific anti-HER antibodies
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
AU2010234916A1 (en) * 2009-03-30 2011-10-13 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
US9050341B2 (en) * 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche highly concentrated anti-CD20 antibody of pharmaceutical formulations. Use of the formulation. treatment method.
NO2719708T3 (en) * 2009-11-13 2018-03-24
AR079256A1 (en) * 2009-12-04 2012-01-04 Genentech Inc Method for the treatment of metastatic breast cancer with trastuzumab-MCC-dm1
US8937159B2 (en) * 2009-12-16 2015-01-20 Abbvie Biotherapeutics Inc. Anti-HER2 antibodies and their uses
US8609095B2 (en) * 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
GB201019467D0 (en) * 2010-11-17 2010-12-29 Biotecnol Sa Therapeutic agent
JP6297490B2 (en) * 2011-08-31 2018-03-20 ジェネンテック, インコーポレイテッド Diagnostic marker
PE23632014A1 (en) 2011-10-14 2015-01-30 Genentech Inc Uses and article of manufacture which includes dimerization inhibitor pertuzumab her2
SG11201402536PA (en) 2011-11-23 2014-06-27 Medimmune Llc Binding molecules specific for her3 and uses thereof
AR094403A1 (en) 2013-01-11 2015-07-29 F Hoffmann-La Roche Ag Combination therapy of anti-HER3
CN103113365B (en) * 2013-02-22 2015-06-17 苏州大学 Rhodanine quinazolinamine compound as well as preparation method and application thereof
WO2014145751A2 (en) * 2013-03-15 2014-09-18 The Translational Genomics Research Institute Targeted therapies for cancer
WO2014172371A2 (en) 2013-04-16 2014-10-23 Genentech, Inc. Pertuzumab variants and evaluation thereof
SG11201608912VA (en) 2014-04-25 2016-11-29 Genentech Inc Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
US10206924B2 (en) 2014-12-15 2019-02-19 The Regents Of The University Of Michigan Small molecule inhibitors of EGFR and PI3K
CN106146412B (en) * 2015-03-31 2019-05-24 广州市恒诺康医药科技有限公司 Quinazoline derivant and its preparation method and application
US20190030181A1 (en) 2015-05-30 2019-01-31 Genentech, Inc. Methods of treating her2-positive metastatic breast cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
WO2018125589A1 (en) 2016-12-28 2018-07-05 Genentech, Inc. Treatment of advanced her2 expressing cancer
WO2018136412A2 (en) 2017-01-17 2018-07-26 Genentech, Inc. Subcutaneous her2 antibody formulations
US20180250397A1 (en) 2017-03-02 2018-09-06 Genentech, Inc. Adjuvant treatment of her2-positive breast cancer
TW201902509A (en) 2017-04-24 2019-01-16 美商建南德克公司 Erbb2 / her2 mutation

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DK0474727T3 (en) * 1989-05-19 1998-01-12 Genentech Inc HER2 extracellular domain
LU91067I2 (en) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and derivatives chemical immuno including immotoxines
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0861893A3 (en) * 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US5777195A (en) * 1996-05-17 1998-07-07 The Rockefeller University Knockout mutant mouse for DARPP-32 and use thereof
US7371376B1 (en) * 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
SI1900751T1 (en) * 1996-11-27 2010-03-31 Genentech Inc Affinity purification of polypeptide on protein a matrix
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
ES2308836T3 (en) 1998-03-27 2008-12-01 Genentech, Inc. Synergy of anti-HER-2 antibodies and ligands to apo l'-2.
IL139035D0 (en) 1998-05-06 2001-11-25 Genentech Inc Protein purification by ion exchange chromatography
US6573043B1 (en) * 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
AU782325B2 (en) * 1999-05-14 2005-07-21 Genentech Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
BR0012195A (en) * 1999-06-25 2002-07-23 Genentech Inc Method for treating prostate cancer in a human, article of manufacture and the use of an antibody which binds ErbB2
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) * 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
KR20090024308A (en) * 1999-08-27 2009-03-06 제넨테크, 인크. Dosages for treatment with anti-erbb2 antibodies
ME00328B (en) * 1999-11-11 2011-05-10 Osi Pharmaceuticals Llc Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
CA2407556C (en) * 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US6984494B2 (en) * 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
WO2003087131A2 (en) 2002-04-10 2003-10-23 Genentech, Inc Anti-her2 antibody variants
PT1585966E (en) * 2002-07-15 2012-02-20 F.Hoffmann-La Roche Ag, Treatment of cancer with the anti-erbb2 antibody rhumab 2c4
EP3388452A3 (en) * 2002-09-11 2019-02-20 Genentech, Inc. Protein purification
EP1572972A4 (en) 2002-11-21 2007-11-21 Genentech Inc Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
CA2531595C (en) * 2003-07-28 2015-12-08 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
WO2005099756A2 (en) * 2004-04-08 2005-10-27 Agus David B ErbB ANTAGONISTS FOR PAIN THERAPY
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
US7197982B2 (en) * 2004-06-09 2007-04-03 Alliant Techsystems Inc. Method for detection of media layer by a penetrating weapon and related apparatus and systems
GT200500155A (en) * 2004-06-16 2006-05-15 Therapy resistant cancer platinum
MX2007000723A (en) 2004-07-22 2007-03-12 Genentch Inc Her2 antibody composition.
CA2577133A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
JP2008523073A (en) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッドGenentech,Inc. Selection of patients for treatment with Her inhibitors
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
EP1850874B1 (en) * 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
TW200642695A (en) * 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
US20060212956A1 (en) * 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
US7513940B2 (en) * 2005-04-07 2009-04-07 Rural Technologies, Inc. Air sampling apparatus and method
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
MY157955A (en) * 2005-07-06 2016-08-30 Hoffmann La Roche Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE02072007A1 (en) 2005-07-22 2007-03-09 Genentech Inc Combined treatment of tumors expressing her
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
KR20090019890A (en) * 2006-06-05 2009-02-25 에프. 호프만-라 로슈 아게 Extending survival of cancer patients with elevated levels of egf or tgf-alpha
KR101136763B1 (en) * 2006-08-21 2012-04-24 에프. 호프만-라 로슈 아게 Tumor therapy with an anti-vegf antibody
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies

Also Published As

Publication number Publication date
US20120251530A1 (en) 2012-10-04
WO2007013950A2 (en) 2007-02-01
WO2007013950A9 (en) 2007-03-29
US20150086545A1 (en) 2015-03-26
US20070020261A1 (en) 2007-01-25
AR054566A1 (en) 2007-06-27
US8163287B2 (en) 2012-04-24
WO2007013950A3 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
Haddad et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study
ES2629405T3 (en) Combinations of a drug conjugate-anti-HER2 and docetaxel
Magne et al. Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer
Safran et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity
Zwald et al. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients
Kim et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin
EP1778215B1 (en) Anticancer effect enhancer
Kuzuya Chemoradiotherapy for uterine cancer: current status and perspectives
de Bono et al. The ErbB receptor family: a therapeutic target for cancer
SUNG et al. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MXPA04011311A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases.
CA2716851A1 (en) Combination therapy with c-met and egfr antagonists
MXPA05012155A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases.
NZ553087A (en) Quinazolinone derivatives and their use as B-raf inhibitors
AR074575A1 (en) Benzoimidazole compound-pyrimidin-aminopyridine, iii crystalline form related, pharmaceutical formulation comprising the same and their use for preparing a medicament useful for treating a cancer
MX2007009649A (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer.
WO2009007748A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
MXPA06001636A (en) Melanin concentrating hormone receptor antagonist.
Khalil et al. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer
MX2009002046A (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders.
Glynne-Jones et al. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?
AR080698A1 (en) Antibody or fragment thereof which specifically binds human variant csf -1R, pharmaceutical composition comprising it, its use for the manufacture of a medicament useful for the treatment of cancer and method for determining whether a subject is a candidate for treatment of cancer based and
CL2004000900A1 (en) pharmaceutical combination comprising (i) an antagonist of a receptor selected least 1-3 VEGFR, PDGFR alpha and beta, fgfr1-3, egfr, her2, IGF1R, HGFR or c-kit and (ii) at least one agent and chemotherapeutic or therapeutic use in facials
MX2008008831A (en) Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists.

Legal Events

Date Code Title Description
FC Refusal